Seeking Alpha

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral ...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Seeking Alpha

Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...
Nasdaq

Structure Therapeutics Inc. Announces Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions

Structure Therapeutics to present promising data on ACCG-2671 for obesity and GLP-1 receptor agonists for Parkinson's at ADA 2025. Structure Therapeutics announced two late-breaking poster ...